Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.

Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, Kelemen LE, Goodman MT, Bandera EV, Terry KL, Schoof N, Eng KH, Clay A, Singh PK, Joseph JM, Aben KK, Anton-Culver H, Antonenkova N, Baker H, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Despierre E, Dicks E, Doherty JA, du Bois A, Dürst M, Easton D, Eccles D, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hogdall C, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kelley JL, Kiemeney LA, Klapdor R, Kolomeyevskaya N, Krakstad C, Kjaer SK, Kruszka B, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Liu S, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Moes-Sosnowska J, Narod SA, Nedergaard L, Nevanlinna H, Nickels S, Olson SH, Orlow I, Weber RP, Paul J, Pejovic T, Pelttari LM, Perkins B, Permuth-Wey J, Pike MC, Plisiecka-Halasa J, Poole EM, Risch HA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schmitt K, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Tangen IL, Teo SH, Thompson PJ, Timorek A, Tsai YY, Tworoger SS, Tyrer J, van Altena AM, Vergote I, Vierkant RA, Walsh C, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Gayther SA, Ramus SJ, Sellers TA, Schildkraut JM, Phelan CM, Berchuck A, Chenevix-Trench G, Cunningham JM, Pharoah PP, Ness RB, Odunsi K, Goode EL, Moysich KB

Open source

DOI
10.18632/oncotarget.10215
Published
2016 Oct 25
Container
Oncotarget
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.18632/oncotarget.10215,
  title = {Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.},
  author = {Hampras SS and Sucheston-Campbell LE and Cannioto R and Chang-Claude J and Modugno F and Dörk T and Hillemanns P and Preus L and Knutson KL and Wallace PK and Hong CC and Friel G and Davis W and Nesline M and Pearce CL and Kelemen LE and Goodman MT and Bandera EV and Terry KL and Schoof N and Eng KH and Clay A and Singh PK and Joseph JM and Aben KK and Anton-Culver H and Antonenkova N and Baker H and Bean Y and Beckmann MW and Bisogna M and Bjorge L and Bogdanova N and Brinton LA and Brooks-Wilson A and Bruinsma F and Butzow R and Campbell IG and Carty K and Cook LS and Cramer DW and Cybulski C and Dansonka-Mieszkowska A and Dennis J and Despierre E and Dicks E and Doherty JA and du Bois A and Dürst M and Easton D and Eccles D and Edwards RP and Ekici AB and Fasching PA and Fridley BL and Gao YT and Gentry-Maharaj A and Giles GG and Glasspool R and Gronwald J and Harrington P and Harter P and Hasmad HN and Hein A and Heitz F and Hildebrandt MA and Hogdall C and Hogdall E and Hosono S and Iversen ES and Jakubowska A and Jensen A and Ji BT and Karlan BY and Kellar M and Kelley JL and Kiemeney LA and Klapdor R and Kolomeyevskaya N and Krakstad C and Kjaer SK and Kruszka B and Kupryjanczyk J and Lambrechts D and Lambrechts S and Le ND and Lee AW and Lele S and Leminen A and Lester J and Levine DA and Liang D and Lissowska J and Liu S and Lu K and Lubinski J and Lundvall L and Massuger LF and Matsuo K and McGuire V and McLaughlin JR and McNeish I and Menon U and Moes-Sosnowska J and Narod SA and Nedergaard L and Nevanlinna H and Nickels S and Olson SH and Orlow I and Weber RP and Paul J and Pejovic T and Pelttari LM and Perkins B and Permuth-Wey J and Pike MC and Plisiecka-Halasa J and Poole EM and Risch HA and Rossing MA and Rothstein JH and Rudolph A and Runnebaum IB and Rzepecka IK and Salvesen HB and Schernhammer E and Schmitt K and Schwaab I and Shu XO and Shvetsov YB and Siddiqui N and Sieh W and Song H and Southey MC and Tangen IL and Teo SH and Thompson PJ and Timorek A and Tsai YY and Tworoger SS and Tyrer J and van Altena AM and Vergote I and Vierkant RA and Walsh C and Wang-Gohrke S and Wentzensen N and Whittemore AS and Wicklund KG and Wilkens LR and Wu AH and Wu X and Woo YL and Yang H and Zheng W and Ziogas A and Gayther SA and Ramus SJ and Sellers TA and Schildkraut JM and Phelan CM and Berchuck A and Chenevix-Trench G and Cunningham JM and Pharoah PP and Ness RB and Odunsi K and Goode EL and Moysich KB},
  year = {2016},
  journal = {Oncotarget},
  doi = {10.18632/oncotarget.10215},
  url = {https://doi.org/10.18632/oncotarget.10215}
}

RIS

TY  - JOUR
TI  - Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
AU  - Hampras SS
AU  - Sucheston-Campbell LE
AU  - Cannioto R
AU  - Chang-Claude J
AU  - Modugno F
AU  - Dörk T
AU  - Hillemanns P
AU  - Preus L
AU  - Knutson KL
AU  - Wallace PK
AU  - Hong CC
AU  - Friel G
AU  - Davis W
AU  - Nesline M
AU  - Pearce CL
AU  - Kelemen LE
AU  - Goodman MT
AU  - Bandera EV
AU  - Terry KL
AU  - Schoof N
AU  - Eng KH
AU  - Clay A
AU  - Singh PK
AU  - Joseph JM
AU  - Aben KK
AU  - Anton-Culver H
AU  - Antonenkova N
AU  - Baker H
AU  - Bean Y
AU  - Beckmann MW
AU  - Bisogna M
AU  - Bjorge L
AU  - Bogdanova N
AU  - Brinton LA
AU  - Brooks-Wilson A
AU  - Bruinsma F
AU  - Butzow R
AU  - Campbell IG
AU  - Carty K
AU  - Cook LS
AU  - Cramer DW
AU  - Cybulski C
AU  - Dansonka-Mieszkowska A
AU  - Dennis J
AU  - Despierre E
AU  - Dicks E
AU  - Doherty JA
AU  - du Bois A
AU  - Dürst M
AU  - Easton D
AU  - Eccles D
AU  - Edwards RP
AU  - Ekici AB
AU  - Fasching PA
AU  - Fridley BL
AU  - Gao YT
AU  - Gentry-Maharaj A
AU  - Giles GG
AU  - Glasspool R
AU  - Gronwald J
AU  - Harrington P
AU  - Harter P
AU  - Hasmad HN
AU  - Hein A
AU  - Heitz F
AU  - Hildebrandt MA
AU  - Hogdall C
AU  - Hogdall E
AU  - Hosono S
AU  - Iversen ES
AU  - Jakubowska A
AU  - Jensen A
AU  - Ji BT
AU  - Karlan BY
AU  - Kellar M
AU  - Kelley JL
AU  - Kiemeney LA
AU  - Klapdor R
AU  - Kolomeyevskaya N
AU  - Krakstad C
AU  - Kjaer SK
AU  - Kruszka B
AU  - Kupryjanczyk J
AU  - Lambrechts D
AU  - Lambrechts S
AU  - Le ND
AU  - Lee AW
AU  - Lele S
AU  - Leminen A
AU  - Lester J
AU  - Levine DA
AU  - Liang D
AU  - Lissowska J
AU  - Liu S
AU  - Lu K
AU  - Lubinski J
AU  - Lundvall L
AU  - Massuger LF
AU  - Matsuo K
AU  - McGuire V
AU  - McLaughlin JR
AU  - McNeish I
AU  - Menon U
AU  - Moes-Sosnowska J
AU  - Narod SA
AU  - Nedergaard L
AU  - Nevanlinna H
AU  - Nickels S
AU  - Olson SH
AU  - Orlow I
AU  - Weber RP
AU  - Paul J
AU  - Pejovic T
AU  - Pelttari LM
AU  - Perkins B
AU  - Permuth-Wey J
AU  - Pike MC
AU  - Plisiecka-Halasa J
AU  - Poole EM
AU  - Risch HA
AU  - Rossing MA
AU  - Rothstein JH
AU  - Rudolph A
AU  - Runnebaum IB
AU  - Rzepecka IK
AU  - Salvesen HB
AU  - Schernhammer E
AU  - Schmitt K
AU  - Schwaab I
AU  - Shu XO
AU  - Shvetsov YB
AU  - Siddiqui N
AU  - Sieh W
AU  - Song H
AU  - Southey MC
AU  - Tangen IL
AU  - Teo SH
AU  - Thompson PJ
AU  - Timorek A
AU  - Tsai YY
AU  - Tworoger SS
AU  - Tyrer J
AU  - van Altena AM
AU  - Vergote I
AU  - Vierkant RA
AU  - Walsh C
AU  - Wang-Gohrke S
AU  - Wentzensen N
AU  - Whittemore AS
AU  - Wicklund KG
AU  - Wilkens LR
AU  - Wu AH
AU  - Wu X
AU  - Woo YL
AU  - Yang H
AU  - Zheng W
AU  - Ziogas A
AU  - Gayther SA
AU  - Ramus SJ
AU  - Sellers TA
AU  - Schildkraut JM
AU  - Phelan CM
AU  - Berchuck A
AU  - Chenevix-Trench G
AU  - Cunningham JM
AU  - Pharoah PP
AU  - Ness RB
AU  - Odunsi K
AU  - Goode EL
AU  - Moysich KB
PY  - 2016
JO  - Oncotarget
DO  - 10.18632/oncotarget.10215
UR  - https://doi.org/10.18632/oncotarget.10215
ER  -

APA

SS, H., LE, S., R, C., J, C., F, M., T, D., P, H., L, P., KL, K., PK, W., CC, H., G, F., W, D., M, N., CL, P., LE, K., MT, G., EV, B., KL, T., N, S., KH, E., A, C., PK, S., JM, J., KK, A., H, A., N, A., H, B., Y, B., MW, B., M, B., L, B., N, B., LA, B., A, B., F, B., R, B., IG, C., K, C., LS, C., DW, C., C, C., A, D., J, D., E, D., E, D., JA, D., A, D. B., M, D., D, E., D, E., RP, E., AB, E., PA, F., BL, F., YT, G., A, G., GG, G., R, G., J, G., P, H., P, H., HN, H., A, H., F, H., MA, H., C, H., E, H., S, H., ES, I., A, J., A, J., BT, J., BY, K., M, K., JL, K., LA, K., R, K., N, K., C, K., SK, K., B, K., J, K., D, L., S, L., ND, L., AW, L., S, L., A, L., J, L., DA, L., D, L., J, L., S, L., K, L., J, L., L, L., LF, M., K, M., V, M., JR, M., I, M., U, M., J, M., SA, N., L, N., H, N., S, N., SH, O., I, O., RP, W., J, P., T, P., LM, P., B, P., J, P., MC, P., J, P., EM, P., HA, R., MA, R., JH, R., A, R., IB, R., IK, R., HB, S., E, S., K, S., I, S., XO, S., YB, S., N, S., W, S., H, S., MC, S., IL, T., SH, T., PJ, T., A, T., YY, T., SS, T., J, T., AM, V. A., I, V., RA, V., C, W., S, W., N, W., AS, W., KG, W., LR, W., AH, W., X, W., YL, W., H, Y., W, Z., A, Z., SA, G., SJ, R., TA, S., JM, S., CM, P., A, B., G, C., JM, C., PP, P., RB, N., K, O., EL, G., & KB, M. (2016). Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.. Oncotarget. https://doi.org/10.18632/oncotarget.10215

Source records